Current Strategies to Overcome Resistance to ALK-Inhibitor Agents.
about
Is there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis.The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
P2860
Current Strategies to Overcome Resistance to ALK-Inhibitor Agents.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Current Strategies to Overcome Resistance to ALK-Inhibitor Agents.
@en
type
label
Current Strategies to Overcome Resistance to ALK-Inhibitor Agents.
@en
prefLabel
Current Strategies to Overcome Resistance to ALK-Inhibitor Agents.
@en
P50
P1476
Current Strategies to Overcome Resistance to ALK-Inhibitor Agents.
@en
P2093
Francesca Simionato
P304
P356
10.2174/1389200216666150812142059
P407
P577
2015-08-12T00:00:00Z